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Background: The human diet has altered markedly during the past four decades, with the introduction of Trans
hydrogenated fat, which extended the shelf-life of dietary oils and promoted a dramatic increase in elaidic acid
(Trans-18.1) consumption. Food additives such as monosodium glutamate (MSG) and aspartame (ASP) were
introduced to increase food palatability and reduce caloric intake. Nutrigenomics studies in small-animal models are
an established platform for analyzing the interactions between various macro- and micronutrients. We therefore
investigated the effects of changes in hepatic and adipose tissue gene expression induced by the food additives
ASP, MSG or a combination of both additives in C57Bl/6 J mice fed a Trans fat-enriched diet.
Methods: Hepatic and adipose tissue gene expression profiles, together with body characteristics, glucose
parameters, serum hormone and lipid profiles were examined in C57Bl/6 J mice consuming one of the following
four dietary regimens, commencing in utero via the mother’s diet: [A] Trans fat (TFA) diet; [B] MSG + TFA diet;
[C] ASP + TFA diet; [D] ASP + MSG + TFA diet.
Results: Whilst dietary MSG significantly increased hepatic triglyceride and serum leptin levels in TFA-fed mice, the
combination of ASP + MSG promoted the highest increase in visceral adipose tissue deposition, serum free fatty
acids, fasting blood glucose, HOMA-IR, total cholesterol and TNFα levels. Microarray analysis of significant
differentially expressed genes (DEGs) showed a reduction in hepatic and adipose tissue PPARGC1a expression
concomitant with changes in PPARGC1a-related functional networks including PPARα, δ and γ. We identified 73
DEGs common to both adipose and liver which were upregulated by ASP + MSG in Trans fat-fed mice; and an
additional 51 common DEGs which were downregulated.
Conclusion: The combination of ASP and MSG may significantly alter adiposity, glucose homeostasis, hepatic and
adipose tissue gene expression in TFA-fed C57Bl/6 J mice.
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Obesity and nonalcoholic fatty liver disease (NAFLD)
are comorbid conditions which are increasingly preva-
lent throughout the world [1]. Several dietary factors
have been implicated as causative, including excessive
sucrose, fructose and fat [2-4]. The human diet has
changed greatly during the past four decades, with the
introduction of partially-hydrogenated vegetable oils
(Trans fats), which began replacing natural fats and oils
in processed foods during the 1960s. Trans fat (TFA)
has no nutritional value, and has been associated with
major health deficits [5]. In 1994, it was estimated that
TFA consumption could be linked to the approximately
20,000 fatalities from heart disease annually in the
United States alone [6]. Increased abdominal adiposity
has been shown to result from TFA-feeding in monkeys
[7]; and increased visceral fat and hepatic lipid accumu-
lation together with impaired insulin sensitivity were
noted in rats consuming a low fat diet supplemented
with 4.6% elaidic acid (Trans-18.1), which is the pre-
dominant lipid found in hydrogenated vegetable oils [8].
Furthermore, we have previously investigated the chan-
ges in hepatic and adipose tissue gene expression which
accompany the increased adiposity and hepatic steatosis
induced by TFA supplementation, and noted significant
dysregulation in several key transcription factors con-
trolling energy metabolism [9].
In addition to extending the shelf life of foods and
reducing production costs, processed foods can be
rendered more palatable by the use of food additives to
preserve flavor and enhance taste [10]. Two of the most
commonly consumed food additives are monosodium
glutamate (MSG) which enhances flavor when combined
with another savory odor [11]; and the low-calorie artifi-
cial sweetener aspartame [12], used to replace dietary
sugar and fructose. However in rodents, neonatal injec-
tions of high doses of MSG promotes obesity and
growth hormone defects together with hyperinsulinemia
and elevated corticosteroid levels in adulthood [13-16].
This hypothalamic model of obesity may also be induced
in the offspring of pregnant dams orally ingesting MSG
[17-19]; and studies with radiolabeled 3H-glutamate have
shown that glutamate given orally to pregnant mice can
subsequently be detected in the maternal and fetal
brains, livers and kidneys [20]. The mechanism behind
the neuroendocrine disturbance caused by MSG is
believed to involve glutamate-induced degeneration of
those areas of the immature neonatal brain which are in-
sufficiently protected by a mature blood–brain barrier,
including regions which regulate growth and energy me-
tabolism [13-19].
MSG has previously been demonstrated to cause
hepatic microsteatosis and a NASH-type phenotype in
rodents exposed to MSG neonatally [21]. We havepreviously shown that the combination of TFA and
MSG can further modulate hepatic and adipose tissue
gene expression, by increasing the transcription of genes
involved in lipid mobilization and storage, together with
an attenuation of the expression of several lipid catabo-
lizing genes [9]. In both tissues, transcription factor
Srebp1c was increased by TFA consumption; whereas in
the adipose tissue, expression of the key transcription
factor Peroxisome proliferator-activated receptor-gamma
coactivator-1alpha (Ppargc1a) was reduced by 50% in
TFA-fed mice, and reduced further to 25% by the com-
bination of TFA and MSG. Ppargc1a is a potent tran-
scriptional activator of glucose and lipid metabolism
linking nutritional and hormonal signals and energy
metabolism; and Ppargc1a-null mice develope systemic
dyslipidemia and hepatic steatosis [22].
The low-calorie dipeptide artificial sweetener aspar-
tame (ASP) is rapidly metabolized upon ingestion into
its metabolic components phenylalanine, aspartate and
methanol, in the ratio of 50:40:10 w/w/w [23]. Recently,
chronic consumption of aspartame by mature rodents
has been shown to cause hepatocellular injury and a re-
duction in hepatic antioxidant defense capacity [24].
Additionally, we have utilized a rodent model in order to
investigate the interactive effects of chronic exposure to
ASP and MSG, either alone or in combination [25]. We
demonstrated that C57Bl/6 J mice exposed to ASP both
in utero via the mother’s diet, and subsequently through-
out the first five months of life, developed hyperglycemia
and reduced insulin tolerance; and that the combination
of ASP and MSG appeared to interact in further modu-
lating insulin sensitivity in young C57Bl/6 J mice.
Throughout the study, animal exposed to ASP and MSG
were maintained on a Standard Chow diet, which has a
relatively low fat content, (typically of between 5-10%),
however this may not accurately reflect current dietary
trends in the human population [26]. We were therefore
interested to know how consumption of ASP and MSG
might affect the physiology and gene expression of ani-
mals consuming a TFA -enriched diet, since in processed
foods and restaurant fare, TFA, MSG and aspartame
may frequently be consumed together in the same meal.
Since TFA [7-9,27], ASP [24] and MSG [9,21] have all
been implicated in hepatic dysfunction, our aim was to
examine the development of hepatic steatosis, adiposity
and changes in hepatic and adipose tissue gene expres-
sion in response to ASP and MSG, or a combination of
both, in animals maintained on a TFA -enriched diet.
Because exposure to nutritional and environmental
challenges during critical periods of early development
can markedly effect metabolism in later life [28], and
since differentiation of the rodent neuroendocrine sys-
tem regulating energy homeostasis begins during gesta-
tion and continues for a significant period of time after
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ary manipulations in utero via the mother’s diet and
throughout the first five months of life, using an experi-
mental design similar to our previous NAFLD studies
[9,30]. Concentrations of ASP and MSG used through-
out this study were comparable with the Acceptable
Daily Intake for both substances [31,32], which we be-
lieve makes our experimental paradigm an appropriate
model for examining the interaction between com-
monly-consumed food additives. To our knowledge this
is the first article to address the effect of these additives




Our study animals were bred from C57Bl/6 J mice
obtained from The Jackson Laboratory (Maine, USA).
Female breeders were housed and fed a standard chow
diet until 6 weeks of age whereupon they were placed on
one of 4 different dietary regimens for an adjustment
period of 3 weeks prior to mating as described pre-
viously [9,30]. The four diet regimens used in this study
were: [1] TFA control diet: consisting of 20% (w/w)
Partially Hydrogenated Vegetable Shortening (Test
Diet #5C4M containing 8.68% w/w Trans fatty acids;
Test Diet Purina, USA), with ad lib drinking water
[2]. MSG+TFA diet: TFA diet with ad lib drinking water
containing 0.75 g/L of L -Glutamic acid monosodium salt
hydrate (MSG catalog G1626 Sigma Aldrich) [3]. ASP +
TFA diet: TFA diet with ad lib drinking water containing
0.25 g/L Asp-Phe methyl ester (aspartame, ASP, catalog
A5139 Sigma Aldrich) [4]. ASP+MSG+TFA diet: TFA
diet with ad lib drinking water containing 0.25 g/L aspar-
tame and 0.75 g/L monosodium glutamate (see Additional
file 1 for diet composition). Following mating, the 4
groups of breeder dams were maintained on their re-
spective diets throughout the gestation, birth and
nursing period. The offspring used in the following
experiments were weaned onto the same maternal dietary
regimen at 4 weeks of age and maintained on their re-
spective diets for the duration of the study. Male offspring
(n = 15 per diet group) were housed 3 to a cage in an iden-
tical manner as described above. Average body weight was
assessed at 6 & 17 weeks of age. Percentage weight change
between these two time-points was calculated as follows:
% weight change ¼ ðweight at 17 weeks
weight at 6 weeksÞ=weight 100
mean ASP and MSG consumption were calculated from
the amount of aspartame-water and MSG-water con-
sumed, and expressed in mg per Kg body weight. At the
conclusion of the study (20 weeks of age), overnight-fasted subjects were euthanized with a mixture of xylazine
and ketamine, and the blood was collected for analysis of
serum components. Concomitantly, the liver and the
visceral fat (epididymal fat pads, together with adipose
tissue associated with the reproductive organs and
omental-mesenteric fat associated with the digestive
organs) was carefully excised, rinsed in PBS buffer,
blotted dry and weighed to the nearest 0.01 g. Tissues
were either snap-frozen in liquid nitrogen for RNA
isolation and hepatic lipid quantitation, or immediately
placed in 5× volume of formalin for histological ana-
lysis. The breeding and care of the animals were in ac-
cordance with the protocols approved by the Animal
Care and Use Committee of the King Faisal Specialist
Hospital & Research Centre.
Measurement of fasting serum glucose, hormone, and
lipid profile
Overnight fasting blood glucose was measured from the
tail vein of the 6-week and 17-week old experimental
subjects using the Ascensia Contour glucometer (Bayer
HealthCare, IN, USA). Additionally, total cholesterol
(T-CHOL), and HDL-C concentrations were also mea-
sured in overnight fasted 17-week old mice using the
Reflovet Plus instrument (Roche, F. Hoffmann-La Roche
Ltd, Basel, Switzerland) as described in our previous
studies [9,30]. A panel of murine hormones and cy-
tokines relating to the metabolic syndrome (amylin,
C-peptide, gastric inhibitory peptide GIP, insulin, leptin,
MCP-1, resistin, and TNFα) were simultaneously ana-
lyzed using the Multiplex bead-based Mouse metabolic
assay catalog# MMHMAG-44 K (Millipore, Billerica,
MA, USA), according to manufacturer’s instructions.
Samples and standards were processed using the
Luminex 100/200 system with related xPONENT® soft-
ware (version 3.1; Luminex Corporation, Austin, TX,
USA). A five-parameter logistic regression model with
weighting was used to create standards curves (pg/mL)
and calculate the mean of sample concentration from
each triplicate. Homeostatic Model Assessment Index
(HOMA-IR) values, a measure of insulin resistance, were
calculated according to the established formula: (fasting
serum glucose mM) * (fasting serum insulin μIU/ml)/
22.5 [33].
Liver and adipose tissue histology, and hepatic
triglyceride quantitation
Formalin-fixed, paraffin-embedded liver and visceral ca-
vity adipose tissues from each of the experimental sub-
jects were processed, and 4 μm-thick serial sections
were cut and stained with hematoxylin and eosin (H&E:
liver) or trichrome (adipose tissue) according to standard
laboratory procedures. After mounting with glycerol ge-
latin, images were captured using Axio Vision Rel4.5
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(Tg) were quantified using the Triglyceride Determin-
ation Kit TRO100 with appropriate triglyceride stan-
dards (Sigma Aldrich, MO, USA). Frozen liver samples
from 20-week old mice were first powdered under liquid
nitrogen and 120 mg of the frozen liver powder was
weighed into 2 ml chloroform: methanol mix (2:1 v/v)
and incubated for 2 hours at room temperature with
continuous shaking. Following the addition of 0.2 vols
H2O, vortexing and centrifuging at 2500 g, the lower
phase chloroform containing the lipids was collected
and dried under vacuum in a rotary evaporator for
5–6 hr. The dried pellets were resuspended in the reac-
tion buffer provided in the Kit. Results were expressed
as mean Tg (mg /g tissue) ± SEM, n = 15 per diet group.
RNA isolation
Animals (n = 15 per diet group) were euthanized at
20 weeks of age by xylazine/ketamine intramuscular
injection, and the liver and adipose tissues were rapidly
removed and rinsed in PBS buffer as described above.
After weighing, the tissues were snap-frozen for RNA
extraction as described previously [9,30]. Total RNA was
prepared using Qiagen RNeasy Kit (Qiagen, CA, USA)
according to the manufacturer’s instructions and
stored at −80°C. RNA integrity was measured using a
2100 Bioanalyzer instrument and an RNA 6000 Nano
LabChip assay (Agilent Technologies, CA, USA). RNA
concentrations were determined by absorption at 260-nm
wavelength with an ND-1000 spectrometer (Nanodrop
Technologies, DE, USA).
Gene expression analysis
Gene expression in these samples was analyzed using 12
GeneChip (R) Mouse Gene 1.0 ST arrays representing
28,853 genes. We used 3 chips per diet group, and ap-
plied pooled RNA from 5 mice per chip (see Figure 1 for
design of the microarray experiments). Targets were pre-
pared and microarrays were processed as described in
the Affymetrix GeneChip Whole Transcript Expression
Analysis manual using the Ambion WT expression kit
and Affymetrix WT Terminal Labeling Kit as per manu-
facturers’ instructions. Briefly, approximately 250 ng of
total RNA was used to synthesize double-stranded DNA
with random hexamers tagged with a T7 promoter se-
quence. The cDNA was used as a template for in vitro
transcription. In the second cycle cDNA synthesis,
random primers were used in reverse transcription to
convert the cRNA into single-stranded DNA, which was
fragmented, labeled, and hybridized to the array for
17 hours, then washed and stained using the Fluidics
450 station (Affymetrix, Santa Clara, CA). Arrays were
scanned using the Affymetrix 3000 7G scanner and
GeneChip Operating Software version 1.4 to produce.CEL intensity files. This software also provided summary
reports by which array QA metrics were evaluated in-
cluding average background, average signal, and 3′/5′
expression ratios for spike-in controls, β-actin, and
GAPDH. Microarray data was deposited at the MIAME
compliant NCBI gene expression hybridization array
data repository (GEO: http://ncbi.nlm.nih.gov/geo) un-
der accession #GSE38444 and GSE38445 (expression data
from liver and adipose tissue respectively).
Quantitative PCR
Confirmation of microarray results was performed by
quantitative PCR (qPCR) as previously described [30].
Total RNA (2 μg) was reverse transcribed using Super-
Script II reverse transcriptase (Invitrogen, CA, USA).
Subsequently, qPCR reactions were performed in tripli-
cate using SYBR-Green 1 master mix (Roche Diagnostics
IN, USA) and 10 ng cDNA as template. No template
and no reverse transcriptase controls were included and
products were analyzed by gel electrophoresis. Real time
qPCR values for each target gene were calculated as a
ratio of target gene expression level to GAPDH expres-
sion level in the same specimen. Statistical significance
was assessed using a two-tailed t test assuming unequal
variance of the biological replicates. Intron-spanning
gene specific primers were designed using Primer 3 soft-
ware and sequences are provided in Additional file 2:
Table S2. DEGs that differed significantly (P < 0.01) in
their regulation between the diet groups’ microarray
analysis were selected, based on their biological rele-
vance, and validated with the same samples by qPCR
analysis. Ratios of expressions between the diet compari-
sons were calculated from the microarray data set and
Pearson correlation analysis between the qPCR and
microarray data were calculated.
Data analysis
Morphological and biochemical data were analyzed
using one-way analysis of variance (ANOVA) followed
by Tukey’s test. Differences were considered significant
at P < 0.05. For identification of differentially expressed
genes (hereafter termed DEGs), microarray analysis was
performed using the Partek Genomic suite software ver-
sion 6.3 (Partek, MO, USA) as previously described
[9,30]. Probe set data were summarized and background
adjusted using the GC-Robust Multi-Array (GCRMA)
algorithm [34], as implemented in the microarray ana-
lysis software package. The GC-RMA algorithm is based
on a linear additive model, and assumes that Ygij =Ogij +
Ngij + Sgij, where Ygij is the perfect match probe intensity
value for probe j in probeset g on array i. Ogij is the cor-
responding “optical noise” due to laser scanning errors,
Ngij is the corresponding “non-specific binding noise,”

















































































































































































































































































































































































































Figure 1 Functional relationship networks of PPAR and PPAR-interacting DEGs responsive to ASP + MSG. IPA-generated networks depict
PPAR-interacting DEGs in (a) Liver & (b) Adipose (P < 0.01, stringency ≥ ± 1.4-fold change in expression).
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tion of the “true” expression value. This method is used to
reduce discrepancies in hybridization patterns from each
of the three chips per diet group that might result from
variables in target amplification, hybridization conditions,
staining or probe array lot. All data were normalized using
non-linear transformation termed Quantile Normalizationto improve the linearity, normality & homoscedasticity
of the data, which was further filtered to remove noise
and extreme expression values. Additionally, all probesets
without unique Entrez gene identifiers were removed from
the analysis. We used a one-way ANOVA to test for diet
interactions without correction for multiple testing. A
significance value of 0.05 indicated that the gene was
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and analysis of the microarray experiments. In order to
identify genes regulated in response to dietary manipula-
tion, we used the False Discovery Rate (FDR) method [35]
in which p-values were adjusted simultaneously across
multiple subgroup comparisons. Contrasts were included
in the model based on the comparison of interest. All
further sub-lists were created using genes that passed the
FDR adjusted ANOVA p-value as well as fold change cri-
teria. A significance value of 0.05 indicated that the gene
was differentially regulated by diet with a stringency of
1.4-fold change in expression values. For identification of
diet-induced differentially expressed genes we considered
the comparison of three conditions (TFA versus ASP +
TFA; TFA versus MSG +TFA; and TFA versus ASP +
MSG+TFA). All resultant genes and expressed sequence
tags (ESTs) meeting the criteria for ASP- and MSG-
induced differential expression were classified as relatively
upregulated or downregulated compared to TFA. Genes
fulfilling these criteria were ascribed genome-wide signifi-
cance using the Database for Annotation, Visualization,
and Integrated Discovery (DAVID) annotation [36]. In-
genuity Pathways Analysis (IPA: www.ingenuity.com) was
used for detection of gene ontology, canonical pathways
analysis, with significant transcripts in diet groups com-
pared to control. Networks of biologically related genes
were also created using IPA. Heat maps of the gene/ESTs
expression data were generated using Matlab (version 7.6,
The MathWorks, Inc. USA) and Partek.
Results
A combination of aspartame and MSG in a Trans fat diet
promotes hyperglycemia, and increases adiposity and
hepatic steatosis
The experimental design is outlined in Additional file 3.
There were no significant differences in food and water
intake between the 4 different diet groups (data not
shown). Mean TFA consumption was 0.02 g/Kg body
weight. Mean aspartame (ASP) and monosodium glu-
tamate (MSG) consumption in the drinking water was
43.54 ± 1.42 mg/Kg body weight and 130.03 ± 5.61 mg/Kg
body weight respectively. Histologically, livers presented
with indications of micro- and macrosteatosis, with the
ASP +MSG diet apparently resulting in the highest degree
of overall steatosis compared to the other diet groups (see
Additional file 4). Trichrome staining of adipose tissue
taken from visceral depots showed a non-significant in-
crease in the apparent size of adipose tissue cells.
Whilst there were no apparent differences in the mean
body weight or weight of liver tissue between all 4 diet
groups, the weight of visceral adipose tissue in the
ASP +MSG + TFA diet group was significantly greater
than all three other diet groups, suggesting the develop-
ment of obesity (Table 1, P = 0.001). Additionally, levelsof plasma free fatty acids (FFA) were significantly ele-
vated in both MSG-containing diet groups (MSG + TFA
and ASP +MSG + TFA). These two diet groups also had
the highest levels of hepatic triglyceride (TG) content in-
dicative of hepatic steatosis (P ≤ 0.001).
Fasting blood glucose levels were highest in the ASP +
MSG + TFA diet group at both 6 and 17 weeks of age
(Table 1, P < 0.001). At 17 weeks of age, fasting blood
glucose levels were markedly higher than the levels at
6 weeks; and the combination of ASP +MSG in the
TFA -fed mice elevated fasting glucose to pre-diabetic
levels [37]. Analysis of hormones and cytokines related
to the development of obesity and hepatic steatosis
showed that both MSG-containing diet groups had
significantly higher levels of serum leptin and TNFα
(MSG + TFA and ASP +MSG + TFA diet mice, Table 1,
P <0.05). Fasting serum insulin levels were increased by
15% in ASP +MSG + TFA diet mice although this obser-
vation failed to reach statistical significance. However,
the HOMA-IR index, an indicator of insulin resistance,
was significantly increased by 56% in ASP +MSG + TFA
diet mice (P < 0.001). Levels of serum amylin and resistin
were not significantly affected by the food additive diets.
In summary, the addition of MSG to the TFA diet raised
hepatic triglyceride and serum leptin levels. The combin-
ation of ASP +MSG promoted visceral adiposity, and el-
evated hepatic triglyceride levels, serum FFA, fasting
blood glucose, TNFα and HOMA-IR index in Trans-fat
fed mice.
We next used Pearson correlation analysis In order to
further understand the mechanism behind the increased
hepatic triglycerides and visceral fat observed in the ASP
and MSG-fed mice. Significant correlations between
levels of hepatic triglyceride content and adipose tissue
weight, FFA, serum cholesterol and leptin were appar-
ent, suggesting the possibility that the mechanism be-
hind the lipid accumulation in the liver could be via
increased adipose tissue mass and flux of FFA to the
liver. HOMA-IR, a strong indicator of the development
of insulin resistance, correlated with body and adipose
tissue weight, fasting glucose, insulin, C-peptide, leptin
and resistin (Table 2, P < 0.05).
Aspartame and MSG modify hepatic and adipose tissue
gene expression
Microarray analysis of hepatic and adipose tissue gene
expression was used in order to further examine the
mechanism behind the diet-induced changes in adiposity
and glucose homeostasis. We used Affymetrix Mouse
Gene 1.0 ST expression arrays to determine differences
in global gene/Expressed Sequence Tags (ESTs), identify-
ing10,117 hepatic gene transcripts and almost 3 times
that number (28,101) of adipose tissue transcripts, with
a significant p-value of 0.05 for diet (see Additional file 3).
Table 1 Body characteristics and biochemical, lipid and hormone profile of experimental subjects
TFA MSG + TFA ASP + TFA ASP +MSG + TFA Sig.
Body Weight (g)
6-week 20.07 ± 0.43 21.29 ± 0.28 20.94 ± 0.26 21.03 ± 0.32 0.06
17-week 31.58 ± 0.77 32.99 ± 0.59 31.37 ± 0.58 32.36 ± 0.87 0.31
% Weight Change 57.58 ± 2.85 54.91 ± 1.59 50.19 ± 3.44 54.78 ± 2.38 0.27
Adipose Weight (g) 1.08a ± 0.13 1.36ab ± 0.09 0.98a ± 0.16 1.67b ± 0.14 0.001
Liver Weight (g) 1.25 ± 0.06 1.23 ± 0.05 1.30 ± 0.03 1.33 ± 0.06 0.49
Liver Triglyceride (mg/ml) 8.12a ± 0.65 12.14b ± 1.00 9.90ab ± 1.16 13.33b ± 0.84 0.001
T_CHOL (mmol/dL) 121.60a ± 1.34 121.67a ± 3.25 127.0ab ± 1.62 130.13b ± 1.54 0.01
HDL (mmol/dL) 87.43 ± 4.08 89.39 ± 4.61 96.75 ± 1.22 98.09 ± 2.91 0.08
Free Fatty Acids (μM) 156.99ab ± 4.59 177.36bc ± 7.73 146.2a ± 5.30 190.03c ± 5.36 <0.0001
Fasting Glucose (mg/dL)
6-week 45.00a ± 2.10 52.03ab ± 3.41 62.50b ± 3.09 92.50c ± 3.87 <0.0001
17-week 98.53ac ± 8.05 117.43ab ± 10.21 81.97c ± 6.53 132.90b ± 8.23 <0.001
Insulin (pg/ml) 525.5 ± 55.6 552.51 ± 56.57 539.73 ± 43.84 606.46 ± 54.50 0.75
HOMA-IR 3.65a ± 0.38 4.67ab ± 0.27 3.06a ± 0.31 5.86b ± 0.70 <0.001
C-Peptide (pg/ml) 1761.88a ± 200.3 1708.5a ± 123.17 1078.42b ± 86.51 1994.65a ± 150.65 <0.001
Amylin (pg/ml) 58.38 ± 5.39 58.82 ± 5.55 64.74 ± 4.24 59.75 ± 4.82 0.81
GIP (pg/ml) 129.13ab ± 17.9 95.46b ± 7.37 143.68c ± 11.91 113.75ac ± 8.69 0.04
Leptin (pg/ml) 5096.68a ± 662.7 9073.34b ± 1319.8 5460.9a ± 979.17 10917.55b ± 716.01 <0.001
MCP-1 (pg/ml) 69.06a ± 7.26 55.09a ± 6.03 69.05a ± 7.96 39.58b ± 4.53 0.01
Resistin (ng/ml) 25.24 ± 1.64 23.12 ± 1.33 21.64 ± 1.24 25.33 ± 1.67 0.26
TNF-α (pg/ml) 11.35a ± 1.35 7.77a ± 1.97 9.59a ± 1.40 30.56b ± 11.44 0.03
HOMA-IR Homeostasis model of assessment of insulin resistance, GIP Gastric inhibitory polypeptide, MCP-1 Monocyte chemotactic peptide-1. Data are presented
as Means ± SEM (n = 15 per diet group). Significant differences in Means are indicated using different letters abc for p-value of <0.05.
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MSG or a combination of both on gene expression in
Trans fat-fed mice, we next identified subsets of ASP-
induced and MSG-induced DEGs using a false discovery
rate as described by Benjamini and Hochberg, with a
significance set at 0.05 and a stringency of ± 1.4-fold. We
identified 8327 liver transcripts which were differentially
expressed by either ASP, MSG or a combination of the
two compared to the TFA-fed control, and a correspond-
ing 11,600 adipose tissue transcripts. These DEGs were
further bifurcated into either down- or up-regulated in
response to the food additives (see Additional file 5). We
identified subsets of 1715 DEGs upregulated by ASP in
the liver and 2599 DEGs upregulated by ASP in the adi-
pose tissue. In both tissues, MSG upregulated the lowest
number of DEGs: 1017 in the liver and 1249 in the adi-
pose tissue. Interestingly, the combination of ASP +MSG
upregulated the highest number of DEGs in the adipose
tissue (2691) compared to approximately half as many in
the liver (1148). Broadly speaking, the number of ASP-
and MSG-induced downregulated DEGs was similar to
the number upregulated, the exception being in theadipose tissue, where MSG down-regulated approximately
half the number of upregulated DEGs. In summary, in
terms of global gene activation, the adipose tissue appears
to be more responsive to dietary manipulation compared
to the liver, and the combination of ASP +MSG induced
the highest number of DEGs compared to either food
additive alone.
Functional gene ontology analysis of food
additive-responsive DEGs
In order to further classify the nature of the food additive-
responsive gene activation in TFA -fed mice, we examined
the functional gene ontologies of the diet-responsive
DEGs in both liver and adipose tissue. Additional file 6
summarizes the main significant ontologies of up- and
down-regulated DEGs induced by ASP, MSG or a combin-
ation of the two, in the livers and adipose tissue of TFA -
fed mice. MSG induced hepatic gene expression related to
blood vessel morphology, transportation of molecules,
and uptake of lipids. Conversely, genes related to RNA
expression, proliferation, mitosis and xcell death were
down-regulated. In adipose tissue, MSG induced genes
Table 2 Correlations of HOMA-IR and hepatic triglyceride
(TG) levels with markers of weight gain, adiposity and
dyslipidemia




Weight gain (%) .355** .387**
Adipose weight (g) .565** .551**
Liver weight (g) .358** .174
Liver TG (mg/ml) 1 .263
T_CHOL (mmol/dL) .439** -.027




Insulin (pg/ml) -.063 .742**
HOMA-IR .260 1
C-peptide (pg/ml) .235 .620**
Leptin (pg/ml) .555** .519**
MCP-1 (pg/ml) -.376* -.207
Resistin (ng/ml) -.044 .403**
Significant correlations are indicated in bold by ** at the 0.01 level and * at
the 0.05 level (2-tailed). TG triglyceride.
Significant correlations are indicated in bold by ** at the 0.01 level and * at
the 0.05 level (2-tailed). TG triglyceride.
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and quantity of mononuclear leukocytes, whereas genes
relating to glucose metabolism disorders and Diabetes
Mellitus were down-regulated (p < 0.05).
A different pattern of gene expression ontologies was
seen in ASP-treated mouse tissues, with the significant
upregulation of genes involved in the organization of the
cytoplasm, morphology of blood vessels and angiogenesis,
and the down-regulation of genes with ontologies relating
to hepatic protein metabolism, organization of peroxi-
somes and expression of RNA (see Additional file 6).
ASP-induced genes relating to cell proliferation and
the development of blood vessels were upregulated in
the adipose tissue of TFA -fed mice; whereas down-
regulated ontologies included adipogenesis and the pro-
liferation of immune cells. Common gene ontologies
significantly induced by the combination of ASP +MSG
included morphology of vessels, vasculogenesis and fatty
acid metabolism, whereas hepatic genes relating to hepatic
expression of RNA and cell cycle progression was
downregulated in all 3 cases. In adipose tissue, similarities
in the ontologies of significant DEGs upregulated by both
food additives included vasculogenesis, angiogenesis and
response to macrophages, whereas down-regulated DEGsrelated to proliferation of leukocytes and the metabolism
of glucose.
Generation of networks of diabetogenic peroxisome
proliferator-activated receptor (PPAR) genes
Since the combination of MSG and aspartame promoted
the largest changes in adiposity, blood glucose and lipid
dysregulation in TFA -fed mice, we next generated
networks of differentially expressed genes which were
dysregulated in response to both ASP and MSG feeding.
We were particularly interested in transcripts associated
with the dysregulation of PPAR genes, since it is known
that PPAR transcriptional activity is affected by diet and
adiposity, and particularly dysregulated by diabetes [37].
Figure 1a shows networks of significant hepatic PPAR
DEGs up-regulated (red) or down-regulated (green) by
the combination of ASP +MSG in the livers of TFA -fed
mice. Key “Master switch” transcription factor Ppargc1a
expression was reduced by 1.7-fold, conversely levels of
hepatic Pparα and Pparδ were modestly increased in this
experimental model. Lipogenic cholesterol homeostasis
transcription factor Srebf2 was upregulated 1.6-fold, to-
gether with a similar increase in cyclic AMP responsive
element binding protein Creb1 (P < 0.05). Additionally,
expression of Acetyl-CoA carboxylase ß (Acacb, Acc2),
an important diet-regulated enzyme involved in lipogen-
esis was increased 1.9-fold together with a 1.8-fold in-
crease in carnitine palmitoyltransferase 1c (Cpt1c), one
of the first enzymes in the mitochondrial ß-oxidation of
long chain fatty acids. Another feature of the food-
additive induced gene expression was the upregulation
of PPAR target genes Acetyl CoA thioesterase (Acot1),
CD36 (1.7-fold) and endothelial lipase (Lipg: 1.7-fold)
which are involved in lipid hydrolysis. PPARα-related
genes involved in cholesterol and phospholipid homeosta-
sis such as the ATP-binding cassette transporters Abca1,
Abcb4 and Abcd2 were upregulated approximately 1.5-
fold, additionally we found a 1.7-fold upregulation of the
PPARα marker genes Cyp4a10 and Cyp4a14 and acetyl-
Coenzyme A acyltransferase (Acaa1b); all previously iden-
tified as being upregulated in models of diabetes. Several
genes involved in cellular stress induction and protection
were deregulated by ASP and MSG in TFA-fed mice,
including an increase in Trp53 (p53: 1.42-fold), Car
(Nr1i3; 1.43-fold), Mef2d (1.6-fold) and Hdac5 (1.5-fold);
together with a decrease in hepatic nuclear factor 6
(Onecut1, 2.23-fold), hepatocyte growth factor (HGF, 1.7-
fold), and Stat3 (1.5-fold).
As expected, the adipose tissue of TFA -fed mice
contained many more PPAR-related DEGs in response
to aspartame and MSG consumption (Figure 1b). The
expression of adipose tissue Ppargc1a was reduced by
3.5-fold, together with a 50% reduction in the expression
of PPARs α and γ, suggesting significant disruption of
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and PPARγ, P < 0.05). The transcription of IPA-gene-
rated genes involved in the ß-oxidation of fatty acids and
glucose were modestly down-regulated, such as rate-
limiting enzymes short chain acyl-CoA dehydrogenase
(Acads), very long chain acyl-CoA (Acadvl ) and dehydro-
genase 3-hydroxyacyl CoA dehydrogenase (Ehhadh) and
pyruvate dehydrogenase ß (Pdhb). IPA-generated net-
works also linked adipogenic gene expression to Ppar
transcription factor down-regulation, including increases
in Creb1, Crebbp, Notch1 and Lipin1. Additionally, ex-
pression of other genes related to lipid mobilization and
storage were dysregulated in this model, such as the re-
verse cholesterol transporter genes Abca1 and Abca3,
perilipin5 (Plin5) and apolipoprotein a4 (Apoa4).
Oxidative stress-responsive sirtuins 1 and 2 (Sirt1 and
Sirt2) gene were upregulated by 2.4 - 2.6-fold, together
with a modest but significant increase in the transcrip-
tion factor forkhead box 3 (Foxo3) and its target genes:
Cdkn1b (p27Kip1: 1.41-fold), growth arrest and DNA
damage-inducible protein 45 (GADD45b: 1.88-fold), and
pro-apoptotic Trp53 (4.4-fold). This was accompanied
by a 2.5-fold reduction in p53-binding and regulatory
protein Mdm2, and a 1.7-fold reduction in peroxire-
doxin 5 (Prdx5), known to protect against oxidative
stress. Since PPARs also play an essential role in adi-
pogenesis, we were interested to find changes in gene
expression relating to adipocytes growth and differenti-
ation in Trans fat-fed mice consuming both food addi-
tives. Expression of oncogenic Notch1 was increased by
2.27 fold; which was accompanied by a 1.8-fold increase
in nuclear receptor co-repressor 1 (Ncor1) and a 1.6-fold
increase in histone deacetylase 1 (Hdac1) expression,
suggesting a significant upregulation of this evolutionary
conserved intracellular signaling pathway. Furthermore
levels of a novel adipocyte differentiating gene mediator
(Med23) were increased nearly 3-fold.
The PPAR -downstream adipokine Thrombospondin-1
(Thbs1) was strongly activated in ASP +MSG-fed mice
by 4.6-fold, suggesting the possibility of the development
of inflammation in these tissues. Serum levels of TNFα
were elevated by almost 3-fold in ASP +MSG-fed mice,
however we did not detect a significant increase in adi-
pose tissue TNFα gene expression. Further examination
of adipose tissue gene expression revealed several im-
portant inflammatory genes which were not included in
the adipose tissue PPAR networks, including a 3-fold
increase in colony stimulating factor Csf1, and pro-
inflammatory Interleukin-6 receptor. Expression of 12/
15-lipoxygenase (Alox15), key regulator of pro-inflam-
matory cytokines and chemokines was upregulated by
more than 3-fold; accompanied by 3-fold increases in
macrophage-marker Emr1. Taken together, the PPAR-
related gene networks generated here in response toaspartame and MSG consumption predominantly in-
dicate transcriptional activity related to adipogenesis,
ß-oxidation, peroxisomal and mitochondrial function,
tissue matrix remodeling, lipid storage and mobilization,
and inflammatory mechanisms.
Coordinated dysregulation of adipose tissue genes
involved in glucose and lipid catabolism and ß-oxidation
in ASP +MSG-treated mice
The highest levels of adipose tissue, glucose and plasma
free fatty acids were apparent in Trans fat-fed mice con-
suming both ASP and MSG; and since analysis of PPAR-
related gene networks revealed diet-induced changes in
the expression of some genes involved in fatty acid oxida-
tion, we next focused more specifically on differentially
expressed genes associated with lipolysis, glycolysis, the
citric acid cycle and mitochondrial oxidative phosphoryl-
ation (Ox-Phos), together with other genes with mito-
chondrial and peroxisomal biogenesis functions. Table 3
shows fold-changes in the expression of 60 genes with
these classifications, which were dysregulated by the com-
bination of ASP +MSG by ≥1.40-fold, and indicates that
50% of these were also dysregulated by ASP alone. For ex-
ample in adipose tissue but not liver, we found signifi-
cantly attenuated expression of both short-chain and very
long-chain Acyl-coA dehydrogenase, which catalyze the
first steps in the oxidation of free fatty acids. Expression of
the trifunctional enzyme subunit Hydroxyacyl-CoA de-
hydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydrata-
ses α and ß (Hadha and Hadhb), which catalyzes the last
three steps of mitochondrial ß-oxidation of long chain
fatty acids was also significantly attenuated in Trans fat-
fed mice consuming a combination of ASP and MSG. In
addition to the 50% reduction in expression of adipose tis-
sue PPARα, ASP +MSG-fed mice exhibited a significant
reduction in Enoyl-CoA, hydratase/3-hydroxyacyl CoA de-
hydrogenase (Ehhadh), the second enzyme in the inducible
peroxisomal ß-oxidation pathway. Glycolysis activator
genes 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
2 (Pfkfb2 and Pfkfb4) were upregulated just over 2-fold.
Lastly, the expression of genes involved in mitochon-
drial and peroxisomal biogenesis and apoptosis were
affected by food additive consumption, including a 50%
reduction in expression of mitochondrial transcription
factor A (Tfam), a key activator of mitochondrial tran-
scription as well as a participant in mitochondrial genome
replication. Conversely, an increase in mitochondrial
apoptosis was suggested by the upregulation of p53, E2F
transcription factor 1, caspase 9 and Bax. In the liver, rela-
tively few lipid catabolic genes were significantly down-
regulated compared to the adipose tissue; conversely some
important ß-oxidative genes such as Cpt1c were modestly
upregulated.
Table 3 Diet-specific coordinated dysregulation of adipose tissue genes involved in glucose and lipid catabolism









Peroxisome proliferator-activated recepto rγ, coactivator 1α Ppargc1a −1.94 −4.51 −3.49 0.048
Peroxisome proliferator-activated receptor α Ppara −1.01 −1.99 −2.03 0.052
Carnitine palmitoyltransferase 1B Cpt1b −1.99 −1.46 −1.63 0.028
Acyl-CoA dehydrogenase, short-chain Acads −1.36 −1.32 −1.57 0.024
Acyl-CoA dehydrogenase, very long chain Acadvl −1.32 −1.11 −1.67 0.036
Hydroxyacyl-CoA dehydrogenaseα Hadha −1.14 −1.31 −1.50 0.036
Hydroxyacyl-CoA dehydrogenase ß Hadhb −1.06 −1.43 −1.73 0.051
Citric acid cycle (TCA) genes
Aconitase 1, soluble Aco1 −1.79 −1.69 −1.67 0.003
Isocitrate dehydrogenase 2 (NADP+), mitochondrial Idh2 −1.19 −1.36 −1.44 0.022
Pyruvate dehydrogenase (lipoamide) α2 Pdha2 −1.43 −1.82 −2.36 0.004
Pyruvate dehydrogenase (lipoamide) ß Pdhb −1.30 −1.36 −1.62 0.043
Succinate dehydrogenase complex, subunit B Sdhb −1.32 −1.30 −1.44 0.001
Mitochondrial oxidative phosphorylation genes
NADH dehydrogenase (ubiquinone) 1 α subcomplex 5 Ndufa5 −1.14 −1.19 −1.47 0.007
NADH dehydrogenase (ubiquinone) 1 α subcomplex 12 Ndufa12 −1.21 −1.24 −1.46 0.004
NADH dehydrogenase (ubiquinone) 1ß subcomplex 2 Ndufb2 −1.12 −1.34 −1.55 0.016
NADH dehydrogenase (ubiquinone) 1ß subcomplex 6 Ndufb6 −1.11 −1.31 −1.46 0.050
NADH dehydrogenase (ubiquinone) 1ß subcomplex10 Ndufb10 1.01 −1.20 −1.76 0.010
NADH dehydrogenase (ubiquinone) Fe-S protein 1 Ndufs1 −1.62 −1.46 −2.16 0.006
NADH dehydrogenase (ubiquinone) Fe-S protein 6 Ndufs6 −1.29 −1.38 −1.53 0.037
NADH dehydrogenase (ubiquinone) flavoprotein 1 Ndufv1 −1.16 −1.27 −1.60 0.005
Succinate dehydrogenase complex, subunit B Sdhb −1.32 −1.30 −1.44 0.001
Ubiquinol-cytochrome c reductase, complex 3 subunit 6 Uqcr11 −1.44 −1.44 −1.58 0.006
COX assembly mitochondrial protein homolog Cmc1 −1.17 −2.33 −2.53 0.040
Cytochrome c oxidase subunit 7a polypeptide 1 Cox7a1 −1.34 −1.25 −1.66 0.005
Cytochrome c oxidase, subunit 7b Cox8b −1.32 −1.13 −1.58 0.047
Cytochrome c oxidase assembly homolog Cox11 −1.04 −1.32 −1.46 0.024
COX assembly mitochondrial protein homolog Cmc1 −1.17 −2.33 −2.53 0.040
Uncoupling protein 2 (mitochondrial, proton carrier) Ucp2 1.32 1.43 1.59 0.001
Glycolysis
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 Pfkfb2 1.37 1.99 2.47 0.050
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 Pfkfb4 1.53 2.48 2.85 0.001
Mitochondrial biogenesis & assembly
Polymerase gamma (nuclear encoded) Polg 1.42 1.72 1.94 0.038
Transcription factor A, mitochondrial Tfam −1.38 −1.32 −2.07 0.008
Mitochondrial fission process 1 Mtfp1 −1.37 −1.30 −1.64 0.004
Tu translation elongation factor, mitochondrial Tufm −1.07 2.14 1.68 0.011
G elongation factor, mitochondrial 2 Gfm2 −1.22 −2.30 −2.46 0.034
Mitochondrial ribosomal protein L3 Mrpl3 −1.06 2.03 1.79 0.054
Mitochondrial ribosomal protein L20 Mrpl20 −1.21 −1.41 −1.62 0.024
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Table 3 Diet-specific coordinated dysregulation of adipose tissue genes involved in glucose and lipid catabolism
expressed as significant fold changes (P < 0.05, stringency ≥ ± 1.4-fold change in expression) (Continued)
Mitochondrial ribosomal protein S24 Mrps24 1.53 −2.99 −3.31 0.037
Mitochondrial ribosomal protein S7 Mrps7 −1.12 −1.39 −1.63 0.032
Mitochondrial ribosomal protein S12 Mrps12 −1.36 −1.40 −1.73 0.011
Mitochondrial ribosomal protein S27 Mrps27 −1.16 −1.28 −1.55 0.050
Surfeit 1 Surf1 −1.22 −1.46 −1.57 0.026
Mitochondrial inner membrane organizing system 1 Minos1 −1.02 −1.44 −1.50 0.001
Inner membrane protein, mitochondrial Immt −1.13 −1.33 −1.66 0.009
Peroxiredoxin 5 Prdx5 −1.15 −1.51 −1.70 0.029
DnaJ (Hsp40) homolog, subfamily C, member 27 Dnajc27 −1.48 −1.80 −1.51 0.047
Diablo, IAP-binding mitochondrial protein Diablo 1.14 1.51 1.63 0.007
Mitochondria-dependent apoptosis
BCL2-associated X protein Bax 1.23 1.38 1.66 0.032
Tumor protein p53 Trp53 2.13 3.57 4.39 0.004
Caspase 9 Casp9 1.44 1.86 1.70 0.034
E2F transcription factor 1 E2f1 1.52 1.73 2.60 0.025
Peroxisomal genes
Peroxisomal biogenesis factor 1 Pex1 −1.14 −2.02 −2.05 0.054
Peroxisomal biogenesis factor 5 Pex5 −1.29 −1.55 −1.67 0.039
Peroxisomal biogenesis factor 7 Pex7 −1.10 −1.74 −1.46 0.026
Peroxisomal biogenesis factor 11 α Pex11a −1.11 −1.40 −1.48 0.012
Peroxisomal biogenesis factor 13 Pex13 −1.17 −1.60 −1.43 0.055
Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase Ehhadh −1.40 −1.06 −1.55 0.029
Acetyl-CoA acyltransferase 1 Acaa1a −1.32 −1.35 −1.59 0.056
ATP-binding cassette, sub-family D (ALD), member 1 Abcd1 1.29 1.69 2.09 0.051
Epoxide hydrolase 2 Ephx2 −1.17 −1.62 −1.66 0.010
Calcium homeostasis genes
Calcium homeostasis endoplasmic reticulum protein Cherp 1.55 2.21 2.37 0.002
Calcium homeostasis modulator 2 Calhm2 1.19 1.61 2.09 0.001
Calcium activated nucleotidase 1 Cant1 1.16 1.45 1.86 0.002
Mitochondrial calcium uniporter Ccdc109a 1.11 1.44 1.70 0.047
Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit Cacna1a 1.37 1.65 1.62 0.016
S100 calcium binding protein A8 S100a8 −1.15 −1.60 −1.57 0.033
Mitochondrial calcium uptake 1 Cbara1 −1.08 −1.80 −1.71 0.038
Calcium channel, voltage-dependent, gamma subunit 4 Cacng4 −1.26 −1.63 −1.85 0.000
Calcium binding protein 2 Cabp2 −1.26 −1.71 −1.98 0.015
S100 calcium binding protein A13 S100a13 −1.19 −2.09 −1.99 0.039
Solute carrier family 8 (sodium/calcium exchanger), member 1 Slc8a1 −1.40 −2.28 −2.01 0.042
Calcium channel, voltage-dependent, gamma subunit 8 Cacng8 −1.21 −1.87 −2.13 0.026
Calcium channel, voltage-dependent, T type, alpha 1I subunit Cacna1i −1.21 −1.38 −2.61 0.045
Calcium channel, voltage-dependent, beta 2 subunit Cacnb2 −1.56 −3.66 −2.76 0.037
Calcium channel, voltage-dependent, alpha 2/delta subunit 4 Cacna2d4 −1.77 −3.32 −3.35 0.019
Calreticulin 3 Calr3 −1.19 −1.83 −1.71 0.035
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both liver and adipose tissue
Our data show that the expression of many genes related
to fatty acid catabolism where significantly down-
regulated in the adipose tissue, but to a far lesser extent
in the liver. The final part of our analysis aimed to shed
more light on the nature of genes which were differen-
tially regulated by the additives aspartame and MSG in
both the liver and the adipose tissue of Trans fat-fed
mice, in order to further our understanding of the mech-
anism(s) involved in the dyslipidemia and other meta-
bolic disturbances. Figures 2 and 3 show Venn diagrams
(A) and 2-D heat-maps (B) of sub-lists of DEGs consid-
ered significant only if they were up-regulated by ≥1.4-
fold in response to ASP, MSG or a combination of
the two additives, in both the liver and adipose tissue
(Figure 2, P < 0.05); or down-regulated by the same cri-
teria (Figure 3, P < 0.05). Almost twice as many genes
were up-regulated than down-regulated in both tissues
by the food additives, either alone (i.e. comparison
ASP + TFA versus TFA, and comparison MSG + TFA
versus TFA) or in combination (comparison ASP +
MSG + TFA versus TFA). A total of 598 DEGs were up-
regulated in all 3 comparisons, compared to only 320
down-regulated DEGs. Interestingly, aspartame alone in-
duced the highest number of upregulated DEGs com-
mon to both tissues; followed by MSG; and the lowest
number of upregulated DEGs was induced by the com-
bination of both additives. A total of 73 DEGs common
to both hepatic and adipose tissue were upregulated in
response to a combination of ASP +MSG, and only 51
commonly expressed hepatic and adipose tissue DEGs
were downregulated. Most notably up-regulated were a
number of stress-responsive DEGs including Trp53
(p53), Notch1, phospholipase D2 (Pld2) and xanthine
dehydrogenase (Xdh). Stress / remodeling proteoglycan
Perlecan (Hspg2) was robustly up-regulated together
with LDL-receptor related protein 1 (Lrp1), Plexin D1
(Plxnd1), Rock1, and Neurofibromatosis 1 (Nf1); all
suggesting that food additive consumption may have led
to an upregulation of genes involved in stress, prolifera-
tion, vasculogenesis and angiogenesis in both tissues
(Figure 2b, P < 0.05).
Key transcription factor Ppargc1a was significantly
down-regulated in both tissues but particularly in adi-
pose (Figure 3b); which was accompanied by a 2-fold re-
duction in hepatic expression of the Cl(−)/HCO [3] (−)
anion exchanger 2 (Slc4a2), which is critically involved
in the development of biliary cirrhosis. Two members of
endocytic low density lipoprotein-related protein family
(Lrp) were also down-regulated in both adipose and hep-
atic tissues. Expression of Lrp2, otherwise known as
Megalin, was decreased 3-fold in adipose and 1.7-fold in
liver tissue; whereas functionally-related Lrp4 expressionwas halved in both tissues. We also found a significant re-
duction in the expression of NADPH oxidase 1 involved
in the regulation of superoxide generation, particularly in
ASP + TFA diet comparisons. Fourteen genes were
randomly chosen for further analyzed by qPCR based on
biological relevance. Pearson correlation coefficients be-
tween the microarray analysis and qPCR were calculated.
Ratios of expressions between the diet comparisons calcu-
lated from the microarray data set correlated well with the
ratio calculated from the real-time PCR data (Figure 4, r =
0.641, P < 0.0001). A complete list of these genes and
PCR primers is given in Additional file 2.
Taken together our final analysis suggests that the tran-
scription of a number of functionally related hepatic and
adipose tissue genes and transcription factors can be mod-
ulated in a similar manner by food additive consumption.
These results may allow for informed speculation about
the mechanisms behind the additive-induced metabolic
dysregulation seen in this nutrigenomics model.
Discussion
Our present data suggests that exposure to the food ad-
ditives aspartame (ASP) and monosodium glutamate
(MSG) as part of a Trans fat-enriched diet may cause
metabolic dysregulation and alterations in hepatic and
adipose tissue gene expression. Exposure to these addi-
tives offered continuously in the drinking water either
alone or in combination, commenced in utero via the
mother’s diet and continued throughout the first five
months of life. These metabolic changes were not in-
curred by hyperphagia since all four diet groups ingested
equal amounts of food. We have previously shown that
ASP exposure in C57Bl/6 J mice may promote weight
gain and dysregulation of glucose homeostasis when
consumed together with a standard chow diet (typically
5% dietary lipids) [38]. We have also demonstrated that
ASP may interact with a second widely consumed food
additive MSG to further imbalance glucose homeostasis
in standard chow-fed animals [25]. The level of MSG-
exposure in our model (~130 mg/Kg bw) is considerably
lower than the dosage used in the classic non-genetic
MSG-obese model, in which animals are typically
injected with 4 g/Kg bw MSG for a period of several
days shortly after birth when the blood–brain-barrier
(BBB) is still immature and vulnerable to excitotoxic
damage [14-16,21]. Nevertheless, exposure to MSG and
ASP metabolites in our model began during conception
and continued in utero and throughout life; and we
hypothesize that it is this continuous exposure which
resulted in the metabolic imbalances described herein.
Our early nutrigenomics studies additionally focused
upon lipogenic changes in hepatic and adipose tissue
gene expression incurred as a result of consumption of








































































































































Figure 2 Upregulated gene expression shared by liver and
adipose tissue. (a) Venn diagram displaying numbers of
upregulated DEGs common to both liver and adipose tissue
induced by either ASP, MSG or the combination of both additives.
(b) 2-dimentional heat map of 73 upregulated DEGs common to
both hepatic and adipose tissue (P < 0.05, stringency ≥ ± 1.4-fold
change in expression).
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http://www.nutritionandmetabolism.com/content/10/1/44with MSG [9]. Trans fats are unsaturated fatty acids with
trans double bonds introduced during the catalytic par-
tial hydrogenation process in order to stabilize dietary
fats and prolong their shelf-life. However, an insightful
study by Yu et al. [39] showed that some TFAs such as
elaidic acid are incompletely oxidized in mitochondria
due to the fact that one of the metabolites (5-trans-
tetradecenoyl-CoA) is a poorer substrate for the mito-
chondrial enzyme long chain acyl-CoA dehydrogenase
(Acadl) than its cis isomer 5-cis-tetradecenoyl-CoA.
Elaidic acid is the major fat found in hydrogenated vege-
table oils, and a reduction in the oxidative capacity of
mitochondria for the trans isomer of the elaidic acid
intermediate may result in an accumulation of 5-trans-
tetradecenoyl-CoA in the mitochondrial matrix, which
could potentially increase oxidative stress. In our pre-
vious study [9], TFA-feeding robustly upregulated li-
pid biosynthetic enzymes in the adipose tissue and
liver whilst also promoting increases in the transcription
of mitochondrial uncoupling protein 3 (Ucp3), several
mitochondrial ß-oxidation genes encoding short-,
medium-, long- and very long-chain acyl co-A dehy-
drogenases, together with the citric acid cycle genes
isocitrate dehydrogenase 3 (Idh3) and pyruvate dehydro-
genase complex (Pdhx). The mechanism for this
appeared to involve a 50% reduction in the expression of
the transcription factor Ppargc1a, the master homeo-
static transcriptional controller of mitochondrial biogen-
esis, oxidative phosphorylation and energy metabolism
[40]. Interestingly, the addition of MSG further reduced
the expression of adipose tissue Ppargc1a to 25% of con-
trol levels, together with attenuated expression of Idh3,
Pdhx, Ucp3, and several ß-oxidation genes [9]. In the
present study, we sought to extend our investigation of
hepatic and adipose tissue gene expression to include
the commonly-consumed food additive ASP, since we
have previously shown that ASP may interact with MSG
in vivo to alter glucose homeostasis, and because others
have shown that ASP may disrupt hepatic antioxidant
defenses [24].
In TFA-fed mice, the addition of either ASP or MSG
alone did not increase adiposity, fasting serum glucose,
cholesterol or FFA levels. However in combination, ASP +
MSG significantly elevated all these parameters, and dou-
bled fasting serum leptin and TNFα, whilst promoting insu-





















































































































Figure 3 Downregulated gene expression shared by liver
and adipose tissue. (a) Venn diagram displaying numbers of
downregulated DEGs common to both liver and adipose tissue
induced by either ASP, MSG or the combination of both additives.
(b) 2-dimentional heat map of 51 downregulated DEGs common to
both hepatic and adipose tissue (P < 0.05, stringency ≥ ± 1.4-fold
change in expression).
Collison et al. Nutrition & Metabolism 2013, 10:44 Page 14 of 17
http://www.nutritionandmetabolism.com/content/10/1/44changes were accompanied by striking alterations in gene
transcription, most notably in the adipose tissue deposits
which were significantly larger than those in the additive-
free TFA diet group. This is of interest since white adipose
tissue (WAT) was originally considered to be a passive
depot of triglycerides, transcriptionally inert and seques-
tering or releasing fatty acids under the influence of vari-
ous hormones [41]. However the past 15 years of research
have shown that WAT is a dynamic pleiotropic endocrine
organ responsive to a wide array of chemical, hormonal,
neuronal and environmental signals. In TFA-fed mice, we
identified over 11,000 differentially expressed adipose
transcripts affected by exposure to ASP and MSG com-
mencing in utero, and roughly 8,000 in liver. Others have
also shown higher numbers of adipose tissue differentially
expressed genes (DEGs) compared to liver, both in re-
sponse to fasting [42], and during LPS-induced inflamma-
tion [43]. Most recently, high-fat feeding has been shown
to induce obesogenic gene expression changes in 4 murine
tissues, with adipose tissue producing the second highest
number of DEGs in the following order: skeletal muscle >
adipose > liver > heart [44].
The increased hepatic triglyceride content seen in TFA-
fed mice exposed to both MSG-containing diets was ac-
companied by an increase in the expression of acetyl-CoA
carboxylase ß (Acc2) and carnitine palmitoyltransferase 1
(Cpt1). Previous studies have shown that transcription of
hepatic Acc2 is markedly upregulated by increased food
intake [45], insulin, and dexamethasone [46]. Unlike Acc1
which stimulates lipogenesis, Acc2 is known to inhibit lip-
olysis; and its structure has an N-terminal extension
containing a mitochondrial-targeting motif which allows
Acc2 to associate with Cpt1 on the outer mitochondrial
membrane, thus regulating ß-oxidation at an early stage in
the process [44]. High-fat diets and obesity have pre-
viously been associated with decreased expression of
Ppargc1a, the dominant regulator of oxidative metabolism
[41]; and whereas we have previously shown that Ppargc1a
expression is reduced by intake of TFA compared to low-
fat controls [9], we now demonstrate that levels of this
transcription factor can be further attenuated by ASP +
MSG exposure, both in the liver and particularly in the
visceral adipose tissue. Expression of Ppargc1a is reduced
in insulin resistant tissues [40], during obesity [47] and in
type 2 diabetes [48]; and Ppargc1a knock-out mice exhibit
hepatic steatosis due to a reduction in mitochondrial
r=0.8006
p-value< 0.0001
Figure 4 Correlation of qPCR and microarray data. Scatter plot
shows Correlation of the ratios from the microarray and real-time
PCR data set. Genes that differed significantly (P < 0.01) in their
regulation between the diet groups’ microarray analysis were
selected and validated with the same samples by qPCR analysis.
Ratios of expressions between the diet comparisons calculated from
the microarray data set correlated well with the ratio calculated from
the qPCR data (r = 0.641, P < 0.0001). A complete list of these genes
is shown in Additional file 2.
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upregulation of lipogenic gene expression [49]. A large
number of signaling pathways have been proposed to
regulate Ppargc1a, including thyroid hormone, nitric oxide
synthase, p38 mitogen activated protein kinase
(p38MAPK), sirtulin and β-adrenergic stimulation, to
name but a few [49]. Interestingly, in addition to the re-
duced expression of Ppargc1a in obese subjects [47],
sustained exposure to saturated fatty acids has been
shown to attenuate the expression of Ppargc1a in vitro
[50]; and epigenetic studies have shown a negative correl-
ation between Ppargc1a mRNA content and an increase
in the methylation of the promoter region of Ppargc1a in
the skeletal muscle of patients with type 2 diabetes [51].
In broad terms, diet-induced changes in hepatic gene
expression tended to be less extensive, and did not mir-
ror the coordinated reduction in adipose tissue ß-oxida-
tive gene expression. Reduced Ppargc1a expression was
accompanied by an upregulation of genes involved in
lipid and cholesterol metabolism, cell stress adaptation
and hepatoprotection. Additionally, levels of carnitine
palmitoyltransferase (Cpt1c), an essential enzyme in the
ß-oxidation of long-chain fatty acids was modestly
elevated in the livers of MSG and ASP-treated mice,
together with genes involved in lipid and cholesterol
homeostasis. Markers of significant hepatic microsteatosis
and oxidative damage have previously been noted in the
livers of MSG-treated rodents [21,52,53]; some of which
could be partially attenuated with antioxidant vitamins C
[54], E [55] or both [56]. Long-term ASP exposure has also
been associated with diminished liver function and im-
paired antioxidant defenses [24]. The authors of that study
speculated that the hepatotoxicity could be attributed tothe methanol component of metabolized ASP, since
methanol is a well characterized hepatotoxin [57]. How-
ever in our model the relatively small amount of ASP
offered in the diet would have been insufficient to raise
blood methanol levels to that required to promote hepato-
toxicity; rather, the increased expression of genes with
hepatoprotective ontology may have been deregulated due
to the increased hepatic triglyceride and serum FFA in-
curred by neonatal exposure to the combination of ASP
and MSG.
Although our nutrigenomic evidence points to signifi-
cant differences in the ontology of gene expression be-
tween the adipose tissue and the liver, for example in the
differential expression of ß-oxidative genes; there were a
number of common DEGs which were up- or down-
regulated similarly in both tissues, and may shed more
light on the mechanism for the diet-induced metabo-
lic dysregulation. Some of the most interesting were
adaptogenic, stress-responsive and oxidative DEGs such
as p53, Notch1, Ppargc1a, NADPH oxidase organizer 1
(Noxo1) and xanthine dehydrogenase. The transcrip-
tional activation of p53 facilitates a diverse range of re-
sponses to metabolic challenges including the regulation
of glucose homeostasis, substrate oxidation and OX-
PHOS, mitochondrial integrity, autophagy and apoptosis.
This assists in balancing proliferation and growth with
nutrient availability, whilst attenuating metabolic stress-
induced damage. In the liver, activation of p53 enhances
apoptosis and promotes NAFLD-associated insulin re-
sistance [58]; whilst in the adipose tissue, p53 has been
termed the “guardian of corpulence” for its adaptogenic
role in lipogenesis and in protecting against FFA-
induced ROM and cellular stress [59]. Concomitant with
the ASP +MSG-induced increase in p53 expression, we
also noted a decrease in one of the major p53 binding
and regulating proteins, Mdm2. This protein attaches to
p53, promoting destabilization and removal from the
nucleus, inhibiting its ability to activate transcription
[60]. Thus our data supports the notion that there is
generally an inverse relationship between Mdm2 and
p53 expression via a negative feedback loop [61], sug-
gesting that the diet-induced reduction in Mdm2 assists
in enhancing the activation of p53. In some tissues p53
has been shown to interact with Notch1, a trans-
membrane receptor molecule participating in cell to cell
signaling and which has previously been implicated in
the control of adipogenesis [62]. We observed a diet-
induced increase in the expression of Notch1 in both
the adipose tissue and the liver, and whereas the role of
notch1 in tumorigenesis has been well documented [63],
recent evidence also suggests that notch1 may play a
role in the development of insulin resistance [64] and
may also have several other pleiotropic functions in the
liver [65].
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The extent of visceral and hepatic fat accumulation and
gene expression can be significantly modified by expos-
ure to common food additives consumed as part of a
Trans fat diet. The combination of aspartame and MSG
promoted the highest level of visceral fat deposition and
serum FFA, leptin and TNFá compared to control or ei-
ther additive alone. Further studies are warranted to
examine the effect of food additives, and combinations
of additives on obesogenic gene expression.
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